A Brief introduction on the Challenges and Strategies in Antibody Drug Production
A Brief introduction on the Challenges and Strategies in Antibody Drug Production No content available
pilot-plant-of-chime-biologics
pilot-plant-of-chime-biologics No content available
Going Global – Chime Biologics Embraces Innovation and Quality with Partners
Going Global-Chime Biologics Embraces Innovation and Quality with Partners Foreign biopharmaceutical companies seek CDMO partners with long-term prospects, technology levels, and quality systems aligned with international standards. Jimmy Wei, President of Chime Biologics, highlighted that the company’s competitive edge arises from ensuring product quality, leveraging efficiencies, and maintaining stringent cost controls. July 5, 2024, Shanghai, […]
(中文) 生物类似药中美欧法规速递
Sorry, this entry is only available in 中文. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.
Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy
Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy The agreement combines Domain Therapeutics’ candidate DT-7012 with Chime Biologics’ internationally-recognized manufacturing expertise In June 2023, Domain nominated DT-7012, a Treg depleting anti-CCR8 monoclonal antibody (mAb) with best-in-class potential, which enters Phase I studies in 2025 The CCR8 GPCR […]
Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services for Hope Medicine’s first-in-class monoclonal antibody drug, HMI-115. The first-in-class mAb will benefit endometriosis and androgenetic alopecia […]
Chime Biologics Enters into a Strategic Cooperation Agreement with Korea Kings Pharm to Accelerate the Biosimilar Launch
Chime Biologics Enters into a Strategic Cooperation Agreement with Korea Kings Pharm to Accelerate the Biosimilar Launch Chime Biologics has entered into a strategic collaboration with Kings Pharm for a biosimilar asset, providing cell line development, process development, global GMP manufacturing, commercialization and regulatory filing support. Chime will also supply the commercial production once the […]
Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development
Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development Chime Biologics and Panolos Bioscience have entered into a global strategic collaboration agreement on a novel multi-specific protein drug. Chime Biologics will provide development and manufacturing services to Panolos Bioscience for PB203, a next-generation immuno-oncology drug. September 19, Wuhan, China […]
Chime Biologics Relisted in the Hurun Future Unicorns in the World 2023, Recognized by the Market for Growth
Chime Biologics Relisted in the Hurun Future Unicorns in the World 2023, Recognized by the Market for Growth The Hurun Research Institute recently released the Hurun Future Unicorns in the World 2023, and Chime Biologics was relisted among the Global Gazelle. Wuhan, China, August 17, 2023 – The Hurun Research Institute recently released the Hurun […]